Tvardi Therapeutics, Inc. - Asset Resilience Ratio
Tvardi Therapeutics, Inc. (TVRD) has an Asset Resilience Ratio of 19.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tvardi Therapeutics, Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Tvardi Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Tvardi Therapeutics, Inc. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Tvardi Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Tvardi Therapeutics, Inc. carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.13 Million | 19.87% |
| Total Liquid Assets | $5.13 Million | 19.87% |
Asset Resilience Insights
- Good Liquidity Position: Tvardi Therapeutics, Inc. maintains a healthy 19.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tvardi Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Tvardi Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Tvardi Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.42% | $10.08 Million | $32.07 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $43.83 Million | -- |
| 2022-12-31 | 49.34% | $22.25 Million | $45.10 Million | -12.83pp |
| 2021-12-31 | 62.16% | $153.58 Million | $247.06 Million | +7.13pp |
| 2020-12-31 | 55.04% | $149.24 Million | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more